Nieuw middel voor coronapatiënten die zelf geen antistoffen aanmaken

At the Erasmus MC in Rotterdam, the first corona patients have recently been treated with special antibodies. They do not produce enough antibodies on their own, for example, because they use the immunosuppressive medication after a transplant. The hospital itself calls this a breakthrough.
The drug, called REGEN-Cov, consists of basiliximab and imdevimab. These are two monoclonal antibodies that reduce the ability of the coronavirus to enter the human cell. “It buys, so to speak, time for patients to make their own antibodies. In patients who will never make antibodies, it helps the body’s other immune systems in their fight against the virus,” says internist-infectiologist Bart Rijnders of Erasmus MC, who applied the treatment.

Transplantation

The monoclonal antibodies were manufactured in the laboratory but were discovered in the blood plasma of a patient who had had covid-19. These potent antibodies are given to patients who do not produce antibodies on their own when they arrive at the hospital. This happens to one in three people. “Sometimes these are previously healthy patients. But most often we see it in patients using immunosuppressive drugs, such as after organ or stem cell transplantation or during blood cancer treatment.” Some people don’t produce antibodies even after full vaccination. “So they can still get very sick when they encounter the virus,” Rijnders says.

The new therapy is not yet fully registered, but its use has been approved by the European Medicines Agency (EMA).

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

Generation of an induced pluripotent stem cell line from a Bartter syndrome patient with the homozygote mutation p.A244D (c.731C>A) in SLC12A1 gene

Generation of an induced pluripotent stem cell line from a Bartter syndrome patient with the homozygote mutation p.A244D (c.731C>A) in SLC12A1 geneGeneration of an induced pluripotent stem cell line from a Bartter syndrome patient with the homozygote mutation p.A244D (c.731C>A) in SLC12A1 gene

Bartter Syndrome (BS) is a gaggle of uncommon inherited autosome-recessive illness, which might be attributable to the gene mutations of sodium-potassium-chloride cotransporter gene (SLC12A1). Right here, the urine cells (UCs)

PTPN5 promotes follicle-stimulating hormone secretion through regulating intracellular calcium homeostasis

PTPN5 promotes follicle-stimulating hormone secretion through regulating intracellular calcium homeostasisPTPN5 promotes follicle-stimulating hormone secretion through regulating intracellular calcium homeostasis

Protein tyrosine phosphatase non-receptor kind 5 (PTPN5), additionally known as striatal-enriched protein tyrosine phosphatase (STEP), is very expressed in neurons of the basal ganglia, hippocampus, cortex, and associated constructions, additionally